Canada Moves To Reduce Industry Adverse Action Re-Reporting
The Canadian regulator has clarified that cases identified from the pharmacovigilance online database should only be re-submitted if they contain additional information.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.